NasdaqGS:BCRX

Stock Analysis Report

Executive Summary

BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers oral and small-molecule medicines.

Snowflake

Fundamentals

Slightly overvalued with limited growth.


Similar Companies

Share Price & News

How has BioCryst Pharmaceuticals's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

0.2%

BCRX

4.6%

US Biotechs

3.4%

US Market


1 Year Return

-65.3%

BCRX

-10.1%

US Biotechs

5.4%

US Market

Return vs Industry: BCRX underperformed the US Biotechs industry which returned -10.1% over the past year.

Return vs Market: BCRX underperformed the US Market which returned 5.4% over the past year.


Shareholder returns

BCRXIndustryMarket
7 Day0.2%4.6%3.4%
30 Day-18.8%-2.4%-1.0%
90 Day-27.7%-2.1%-0.4%
1 Year-65.3%-65.3%-9.4%-10.1%7.7%5.4%
3 Year-39.9%-39.9%14.9%10.9%46.2%36.8%
5 Year-78.0%-78.0%2.3%-2.7%65.6%47.5%

Price Volatility Vs. Market

How volatile is BioCryst Pharmaceuticals's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is BioCryst Pharmaceuticals undervalued compared to its fair value and its price relative to the market?

42.0%

Undervalued compared to fair value


Share Price vs. Fair Value

Undervalued: BCRX ($2.5) is trading below our estimate of fair value ($4.31)

Significantly Undervalued: BCRX is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: BCRX is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: BCRX is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

Low PEG Ratio: Insufficient data to calculate BCRX's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: BCRX has negative assets, so we can't compare its PB Ratio to the US Biotechs industry average.


Next Steps

Future Growth

How is BioCryst Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?

32.3%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: BCRX is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: BCRX is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: BCRX is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: BCRX's revenue (63.7% per year) is forecast to grow faster than the US market (7.3% per year).

High Growth Revenue: BCRX's revenue (63.7% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

High Future ROE: Insufficient data to determine if BCRX's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has BioCryst Pharmaceuticals performed over the past 5 years?

-22.7%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: BCRX is unprofitable, and losses have increased over the past 5 years at a rate of -22.7% per year.

Accelerating Growth: Unable to compare BCRX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: BCRX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (78.4%).


Return on Equity

High ROE: BCRX's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets

ROA vs Industry: BCRX is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: BCRX is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is BioCryst Pharmaceuticals's financial position?


Financial Position Analysis

Short Term Liabilities: BCRX has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: BCRX has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: BCRX has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: BCRX's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet

Inventory Level: BCRX has a low level of unsold assets or inventory.

Debt Coverage by Assets: BCRX has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: BCRX has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: BCRX has less than a year of cash runway if free cash flow continues to reduce at historical rates of -23.2% each year


Next Steps

Dividend

What is BioCryst Pharmaceuticals's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.5%markettop25%3.8%industryaverage2.0%forecastin3Years0%

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate BCRX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate BCRX's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if BCRX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if BCRX's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of BCRX's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of BioCryst Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

9.8yrs

Average management tenure


CEO

Jon Stonehouse (58yo)

12.8yrs

Tenure

US$4,167,643

Compensation

Mr. Jon P. Stonehouse has been the Chief Executive Officer and Executive Director of BioCryst Pharmaceuticals, Inc. at Shionogi & Co., Ltd. since joining in January 8, 2007 and also has been its President  ...


CEO Compensation Analysis

Compensation vs. Market: Jon's total compensation ($USD4.17M) is above average for companies of similar size in the US market ($USD1.16M).

Compensation vs Earnings: Jon's compensation has increased whilst the company is unprofitable.


Management Age and Tenure

9.8yrs

Average Tenure

55.5yo

Average Age

Experienced Management: BCRX's management team is seasoned and experienced (9.8 years average tenure).


Board Age and Tenure

5.1yrs

Average Tenure

66yo

Average Age

Experienced Board: BCRX's board of directors are considered experienced (5.1 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

BuyUS$10,71024 May 19
Stephen Aselage
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares3,000
Max PriceUS$3.57
BuyUS$16,60014 Mar 19
Stephen Aselage
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares2,000
Max PriceUS$8.30
SellUS$155,29920 Dec 18
William Sheridan
EntityIndividual
Role
Senior Key Executive
Chief Medical Officer & Senior VP
Shares20,488
Max PriceUS$7.58
SellUS$37,06306 Dec 18
Thomas Staab
EntityIndividual
Role
Chief Financial Officer
CFO, Principal Accounting Officer
Shares3,922
Max PriceUS$9.45
SellUS$174,96004 Dec 18
Alane Barnes
EntityIndividual
Role
Chief Legal Officer
Senior VP
Shares19,290
Max PriceUS$9.07

Ownership Breakdown


Management Team

  • Tom Staab (51yo)

    CFO, Principal Accounting Officer

    • Tenure: 8.3yrs
    • Compensation: US$1.80m
  • John Bluth (46yo)

    Senior Vice President of Investor Relations & Corporate Communications

    • Tenure: 0yrs
  • Bill Sheridan (64yo)

    Chief Medical Officer & Senior VP

    • Tenure: 11.3yrs
    • Compensation: US$2.35m
  • Jon Stonehouse (58yo)

    CEO, President & Director

    • Tenure: 12.8yrs
    • Compensation: US$4.17m
  • Elliott Berger

    Senior Vice President of Regulatory Affairs

    • Tenure: 0yrs
  • Alane Barnes (53yo)

    Senior VP

    • Tenure: 13.3yrs
    • Compensation: US$1.33m
  • Yarlagadda Babu (66yo)

    Senior Vice President of Drug Discovery

    • Tenure: 6yrs
    • Compensation: US$1.76m
  • Robert Stoner

    Vice President of Human Resources

    • Tenure: 0yrs
  • Megan Sniecinski

    Chief Business Officer

    • Tenure: 0.3yrs

Board Members

  • Steve Aselage (68yo)

    Independent Director

    • Tenure: 0.8yrs
  • Bob Ingram (77yo)

    Independent Chairman

    • Tenure: 2.4yrs
    • Compensation: US$213.41k
  • Ken Lee (71yo)

    Independent Director

    • Tenure: 8.3yrs
    • Compensation: US$200.91k
  • George Abercrombie (64yo)

    Independent Director

    • Tenure: 8yrs
    • Compensation: US$180.91k
  • Helen Thackray (51yo)

    Director

    • Tenure: 0.08yrs
  • Theresa Heggie (59yo)

    Independent Director

    • Tenure: 0.8yrs
    • Compensation: US$193.27k
  • Nancy Hutson (70yo)

    Independent Director

    • Tenure: 7.8yrs
    • Compensation: US$190.91k
  • Jon Stonehouse (58yo)

    CEO, President & Director

    • Tenure: 12.8yrs
    • Compensation: US$4.17m

Company Information

BioCryst Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: BioCryst Pharmaceuticals, Inc.
  • Ticker: BCRX
  • Exchange: NasdaqGS
  • Founded: 1986
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$276.096m
  • Shares outstanding: 110.44m
  • Website: https://www.biocryst.com

Number of Employees


Location

  • BioCryst Pharmaceuticals, Inc.
  • 4505 Emperor Boulevard
  • Suite 200
  • Durham
  • North Carolina
  • 27703
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
BCRXNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDMar 1994
BO1DB (Deutsche Boerse AG)YesCommon StockDEEURMar 1994
BCRX *BMV (Bolsa Mexicana de Valores)YesCommon StockMXMXNMar 1994

Biography

BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers oral and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor, for the treatment of a ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/15 23:32
End of Day Share Price2019/10/15 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.